Tao Jiang

8PUBLICATIONS
81CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 10, 2025
Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial.

Shuo Yang, Xinyu Liu, Jia Yu

|Jul 29, 2025
Camrelizumab, an Anti-PD-1 Monoclonal Antibody, Plus Carboplatin and Nab-Paclitaxel as First-Line Setting for Extensive-Stage Small-Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis.

Jia Yu, Deyu Cai, Sha Zhao

|Feb 20, 2025
Differential expression of the MYC-Notch axis drives divergent responses to the front-line therapy in central and peripheral extensive-stage small-cell lung cancer.

Libo Luo, Rui Xia, Shiqi Mao

|Dec 05, 2024
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer.

Haowei Wang, Anwen Xiong, Xiaoxia Chen

|Jul 14, 2023
HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer.

Tao Jiang, Qiqi Jin, Jiahao Wang

|Jul 11, 2023
Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma.

Hong Wu, Xuefeng Leng, Qianshi Liu

Pageof 2

Frequent Collaborators

2 joint publications

Caicun Zhou

2 joint publications

Yaqi Chen

2 joint publications

Guihua Wang

1 joint publications

Changsheng Huang